Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tecelra
Synonyms :
afamitresgene autoleucel
Class :
T Cell Immunotherapies
Brand Name :
Tecelra
Synonyms :
afamitresgene autoleucel
Class :
T Cell Immunotherapies
Adult
Suspension
2.68-10 x 109 MAGE-A4 TCR-positive T cells
Each 250 ml infusion bag carries in a protective metal cassette
Not determined
T-cells are modified to express T-cell receptor specific for MAGE-A4 antigen found on certain tumor cells in afami-cel treatment. Modified T-cells in patient’s body can target and bind to specific cancer cells.
Frequency defined:
>50%
All grades
Lymphocyte count decreased
White blood cell decreased
Red blood cell decreased
Neutrophil count decreased
Platelet count decreased
Cytokine release syndrome
Nausea
Grade 3 or 4
Lymphocyte count decreased
Neutrophil count decreased
White blood cell decreased
>10-50%
All grades
Alanine aminotransferase increased
Vomiting
Fatigue
Infection
Pyrexia
Abdominal pain
Dyspnea
Non-cardiac chest pain
Decreased appetite
Pain in extremity
Alopecia
Back pain
Headache
Cough
Asthenia
Hypotension
Sinus tachycardia
Chills
Chest pain
Dizziness
Weight decreased
Grade 3 or 4
Red blood cell decreased
Platelet count decreased
Non-cardiac chest pain
Asthenia
Dyspnea
Abdominal pain
Alanine aminotransferase increased
Pyrexia
Weight decreased
Infection
Back pain
Nausea
Cytokine release syndrome
Drug interaction:
There is no significant drug interaction available.
Cytokine Release Syndrome is a strong inflammatory reaction when modified T-cells release excess cytokines.
Contraindications:
Hypersensitivity of Heterozygous or homozygous
Cautions:
Immune effector cell-associated neurotoxicity syndrome
Prolonged severe cytopenia
Secondary malignancies
Hypersensitivity reactions
Pregnancy category: Â N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Modified T-cells bind to MAGE-A4-express tumor cells that activates them to release cytotoxic molecules that induce apoptosis in cancer cells. It modifies a patient’s T cells to target MAGE-A4 protein on cancer cells.
Pharmacodynamics:
Perforin makes pores in tumor cell membrane for granzymes to induce apoptosis. Afami-cel release cytokines and chemokines to modify tumor environment for immune attack enhancement.
Pharmacokinetic:
Absorption:
The peak plasma time for median is 7 days.
It is administered intravenously in the injection form.
Generic Name: afamitresgene autoleucel
Why do we use afamitresgene autoleucel?
Afamitresgene autoleucel is indicated in the treatment of synovial sarcoma.
It is used to target solid tumors that express the MAGE-A4 antigen.
It is also considered as treatment option for patients with relapsed or refractory cancers that express MAGE-A4.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
